Prospective, randomized, partly blinded, in part placebo-controlled, multicenter, dose-finding trial exploring safety, tolerability and efficacy of a topical resiquimod gel in patients with multiple actinic keratosis lesions.
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Resiquimod (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Sponsors Spirig Pharma
- 01 Sep 2018 Results published in the British Journal of Dermatology
- 14 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 24 Oct 2013 Planned end date changed from 1 Mar 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.